Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

  • Independent Japanese study demonstrates dramatic benefits of adding Diovan to conventional therapy
  • Study halted early due to superior outcomes for Diovan patients
BASEL, Switzerland, April 27, 2007 - New findings from the independent Jikei Heart Study, published today in The Lancet[1], show that adding the blood pressure lowering medication Diovan® to conventional therapy produced a dramatic 39% reduction in cardiovascular events and a 40% reduction in stroke.
The superior benefits reported with Diovan led to an early termination of the study, which involved more than 3,000 Japanese patients.
In addition to its impact on overall cardiovascular events and stroke, Diovan demonstrated relative reductions of 65% in angina pectoris (recurring acute chest pain), 46% in heart failure and 81% in aortic dissection (separation of the wall layers in the body's main artery) compared to other treatment groups1. According to the investigators, these benefits cannot be explained by a difference in blood pressure alone. There were few adverse events (2.5% overall) with no significant difference in tolerability between the groups.
"The results of this trial carry an important clinical message for physicians across the globe who are trying to protect patients from debilitating complications such as stroke," said Gordon McInnes, MD, Professor of Medicine at the Western Infirmary in Glasgow, Scotland. "Jikei Heart tells us that adding Diovan to usual treatment regimens can offer substantial long-term protection."
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Post Your Comments:
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... ORANGE, Calif. , July 23, 2014 ... will gather in Las Vegas ... event. Spearheaded by educator, author, forward thinker and private ... to bring experts together to candidly discuss clinical and ... two day event is a unique opportunity to welcome ...
(Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3
... Analyzes the Effectiveness and Safety of Statin Use for Those Who Need It , ... Recommendations for Choosing a ,Best Buy, Statin and Strategies for ... YONKERS, N.Y. , June 29 ... ) caution that the benefits of statin use by children and some women may ...
... Initiative Launched on Biosafety , , ... WASHINGTON , June 29 Remember chemistry sets, ham radio, amateur ... 2,000 people from around the world belong to the Do-It-Yourself Biology (DIYbio) community, ... bio-monitoring, to new treatments for diseases. , ...
Cached Medicine Technology:Consumer Reports Health Questions Use of Statins By Children and Some Women 2Consumer Reports Health Questions Use of Statins By Children and Some Women 3Consumer Reports Health Questions Use of Statins By Children and Some Women 4Consumer Reports Health Questions Use of Statins By Children and Some Women 5Consumer Reports Health Questions Use of Statins By Children and Some Women 6Consumer Reports Health Questions Use of Statins By Children and Some Women 7Responsible Science for Do-It-Yourself Biologists 2
(Date:7/23/2014)... July 24, 2014) If past experience is anything ... are about to get a lot more recognition for ... on the books allowing NPs to provide primary care ... care and better relationships with physicians and administrators, compared ... from Columbia University School of Nursing, published in ...
(Date:7/23/2014)... 2014 Celebrating a decade of philanthropy ... announced the awarding of $1,070,000 in grants to 20 ... recognition of the Foundation’s 1,000th grant. , “The Horizon ... tradition of supporting community-based organizations that are working to ... in the Garden State,” said Robert A. Marino, Horizon ...
(Date:7/23/2014)... body of research suggesting a safe and effective ... breast cancer, with fewer detrimental side effects and ... The study will be published in final format ... and Endocrinology . , Breast cancer is the ... United States. Approximately 70% of breast cancers are ...
(Date:7/23/2014)... 23, 2014 Global Cardio Care, Inc., ... External Counterpulsation (EECP), is celebrating the 100th birthday ... at the health center. , Weber has been ... receiving ongoing EECP therapy since 1999, he no longer ... CEO of Global Cardio Care, introduced the Sara ...
(Date:7/23/2014)... The voice on the recording was low and calm as ... was infected with the human immunodeficiency virus (HIV) that causes AIDS: ... you know I was on the floor flat on my face ... when the recording ended less than 10 minutes later. “Don’t feel ... because it is just God setting you up for something greater,” ...
Breaking Medicine News(10 mins):Health News:New York law offers nurses more recognition, responsibility 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3
... cancer center at NYU Langone Medical Center, identified for ... (miRNAs) play in melanoma metastasis to simultaneously cause cancer ... to fight abnormal cells. The new study is published ... Cancer Cell. Researchers performed a miRNA ...
... , MONDAY, July 11 (HealthDay News) -- Too much salt ... risk for cardiovascular disease and death, a new study shows. ... pressure and high levels of salt consumption and low levels ... called sodium -- and low potassium appears to convey a ...
... Dotinga HealthDay Reporter , MONDAY, July 11 ... in their homes face a higher risk of developing ... new study finds. The research doesn,t definitively ... it doesn,t say how much smoke is too much. ...
... By Denise Mann HealthDay Reporter , MONDAY, ... reduce the risk of lasting neurological damage, but this lifesaving ... local hospitals don,t have the proper systems in place, and ... arrest to be effective, according to the report in the ...
... DETROIT Na Zhu, a Wayne State University College ... Association Student Research Grant Program award. The program financially ... a cure for tinnitus. Zhu, a Ph.D. ... Professor in the Department of Mechanical Engineering, is developing ...
... that can accumulate to high levels in our body ... linked to an increased risk of cancer and/or impaired ... by Sridhar Mani, at Albert Einstein College of Medicine, ... between environmental exposure to these foreign chemicals (xenogens) and ...
Cached Medicine News:Health News:Researchers identify key role of microRNAs in melanoma metastasis 2Health News:Study: Potassium Boosts Heart Health, Salt Harms It 2Health News:Study: Potassium Boosts Heart Health, Salt Harms It 3Health News:ADHD, Learning Issues May Be Linked to Secondhand Smoke 2Health News:Coordinated Cooling Effort After Cardiac Arrest Can Improve Outcomes 2Health News:Coordinated Cooling Effort After Cardiac Arrest Can Improve Outcomes 3
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
... is engineered to distribute contact pressure evenly over ... back, to maximize stability and patient comfort. ... readily conformable to patient anatomy, to provide a ... wool liner is standard on both units, as ...
Medicine Products: